References
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med. 2009;361(11):1045–1057.
- Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. Circulation. 2009;120(25):2577–2585.
- Brilinta, US full prescribing information, December 2013. [ cited 2014 Jan 22]. Available from: http://www.azpicentral.com/brilinta/brilinta.pdf#page=1.
- Effient, US full prescribing information, November 2013. [ cited 2014 Jan 22]. Available from: http://pi.lilly.com/us/effient.pdf.
- Plavix PI, US full prescribing information, December 2013. [ cited 2014 Jan 22]. Available from: http://packageinserts.bms.com/pi/pi_plavix.pdf.
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228.
- O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Circulation. 2013;127(4):529–555.
- Smith SC Jr, Benjamin EJ, Bonow RO, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEJM. 2007;357:2001–2015.
- Nylander S, Femia E, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haenost. 2013;11:1867–1876.
- Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Eng J Med. 2015;372(19):1791–1800.